AML Therapy With Irradiated Allogeneic Cells

Inclusion Criteria: * Histologically proven non-M3 AML: * Refractory/relapsed AML OR * Initial diagnosis of AML in patient \>= 60 years old * Total bilirubin =\< 1.5 times upper limit of normal (ULN) institutional limits (unless Gilbert's disease) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional ULN * Cardiac left ventricular ejection fraction (LVEF) \>= 35% * Serum creatinine =\< 1.5 mg/dl * Any organ dysfunction thought to be secondary to disease will be considered separately and the patient will be included at the investigators discretion * Patients must give informed consent * Eastern Cooperative Oncology Group (ECOG) performance status =\< 3 * Must have a potential haploidentical donor (parent, sibling, child) * A patient is eligible for second enrollment (allo-cellular therapy) if all of the following inclusion criteria are met: * Patient must have documented CR or CRp after 1 or 2 cycles of fludarabine + cytarabine * Patient must not be a candidate for an allo-hematopoietic stem cell transplant (HSCT) * Patient must have a partially (\>= 3/6 class I antigen) human leukocyte antigen (HLA)-matched (by serology or low resolution deoxyribonucleic acid \[DNA\] testing) relative able to serve as a donor * Patients must not have active uncontrolled infections, other medical or psychological/social conditions that might increase the…